The inhibitory effects of the different natural royleanones (

-

) were compared in MFC-7, SkBr3, SUM159, and SUM159 grown in CSC-inducing conditions. CSC represents the subpopulation of cancer cells that is responsible for metastasis. Due to their morphological characteristics of growth in spheres, they are referred to as SUM159 spheres. Three-dimensional in vitro models can be considered as an intermediate model between in vitro cancer cell line cultures and in vivo tumor. Different cancer cell lines were used aiming to assess which of the cell development phases is most affected by the action of each abietane compound.

The results showed that increased concentrations of abietanes reduced cell viability (Figure 1). Overall, although Roy (

) and ParvD (

) tend to inhibit MCF-7, SkBr3, and SUM159 cell viability, it was shown to be less effective against the most aggressive type of cells, the cancer stem cells SUM159 sphere. DeRoy (

) showed the highest inhibitory effect on SUM159 spheres, thus indicating its potential to significantly decrease the number of viable CSC cells.

The Protein DataBank (PDB, ^[1]) had the following available protein crystal structures:

: 5F9E;

: 3ZH8, 3AW8, 3A8X (only 3ZH8 has a co-crystallized inhibitor);

: 4RA4; and

II: 2I0E. There are crystal structures of other isomorphs; however, structures 1YRK and 2YUU (

), and 2WH0 (

) do not contain the catalytic domain, while no structure of the

isoform is available. From the percent identity matrix (Table 1), isomorph

seems to be the most similar to isoform

. Based on these results, we took structures 4RA4 for isoform

, 3ZH8 for isoform

as an approximation to

, and 5F9E for isoform

(and as an approximation to isoform

). Isoform

was taken as an approximation to isoform

. 1PTR was taken for isoform

.

The results from the docking runs of all programs, proteins, and ligands (Table 2) showed that ParvD (

), Roy (

), and DeRoy (

) tended to have calculated docking scores close to those of the co-crystallized ligands (i.e., known binders) for all five isoforms studied. The MMGBSA results only showed a favorable calculated docking scores for

in isoforms

,

, and

but not in

. These results for the interaction can be compared to experimental observations showing that compounds

and

are the strongest inhibitors for all cell types. The weakest docking scores correspond to the compounds docked into the PKCδ isoform.

From the data presented in Table 1, Table 2, Table 3, Table 4 and Table 5, we can explain the general trends in the docking scores of royleanones to different isoforms of PKC. Docking calculations report docking scores of up to −9.9 kcal/mol for

and

. From the intermolecular interaction analysis (Table 3),

interacts with 11 amino acid residues in a hydrophobic manner. Kinases share overlapping substrate recognition patterns but specific hydrophobic binding pockets for recognizing bulky hydrophobic residues upstream of the catalytic Ser/Thr distinguish atypical PKCs from other kinases, and this may provide specificity. In addition, although reportedly forming a hydrophobic interaction with the conserved Lys 371, we cannot rule out the possibility for hydrogen bond formation as well, analogous to the case in the

isoform (with a corresponding conserved residue Lys 368). This actually is significantly different to compound

, as

is capable of forming this additional interaction. Moreover, a significant difference in the log

values (Table 5) between

and

makes the latter more favorable for the local hydrophilic environment of the binding site (Thr 404, Lys 371, Met 473, and Met 420, if considered as amphipathic), rather than the more lipophilic

. In addition, if we compare the percent of exposed surface area of the docked conformations in the PKC

isoform,

is more “buried”, and therefore more prone to keeping the bound conformation than

. Regarding

and

, both have similar binding patterns to compounds

and

. However, the Autodock docking score values are contradictory with respect to the experimental inhibition results. Therefore, the explanation may be found in the compounds’ properties.

has a similar log

value and ratio of the exposed surface as

, while

has the highest log

value and a more exposed surface. This is probably the reason for the lower interaction score: The compound is too nonpolar and less buried in the binding site, which contributes to an easier unbinding process. Figure 2 shows the difference in the exposed surface area for

and

.

Compound

shows the best docking score towards the PKC

II isoform (−9.9 kcal/mol), however, without selectivity towards other isoforms. The high predicted affinity may be explained by the formation of more hydrophobic interactions with binding site amino acids than in the case of

and

. In addition,

has a higher log

value, and the ratio between the total solvent-exposed and docked conformation solvent-exposed surface is the lowest in the case of

which indicates a slower unbinding process. Both properties are in favor of a higher predicted affinity towards any of the PKC isoforms.

The difference in docking scores between

and

can be explained by the scoring function’s overestimation of hydrophobic interactions. The docking results identified

and

as the predicted most strongly interacting compounds to all PKC isoforms, although less strongly to

. Finally, the predicted interaction of each compound in different PKC isoforms can be due to subtle but significant amino acid residue changes, such as Met → Leu or Thr → Val and others, which can change the electrostatic nature of the binding site towards being more hydrophobic.

The binding site of PKC

can be seen to be aligned onto PKC

(Figure 3). ParvD (

), DeRoy (

), and RoyBz (

) are moderately sized compounds compared to the others in this series, which may allow for a better fit in the different PKC binding sites, though PKC

has a smaller binding site as compared to the other isoforms.

ParvD (

) has the best interaction profile of

-

, given that it is the most potent compound against all cells studied, including the most aggressive type. The docked binding pose of ParvD (

) in 3ZH8 shows a significant difference with respect to DeRoy (

) (Figure 4), with the royleanone part of ParvD (3) flipped and more towards the entrance to the binding site, and its phenol ring in the hydroxybenzoate functional group interacting deeper, making hydrogen bonds with Val326 (top-right in Figure 4, interactions made instead by the royleanone part in the DeRoy(

) complex). Table 2 also shows that the strongest predicted interaction for the strongest experimental inhibitor, ParvD (

), is with isoform PKC

, 3ZH8, where ParvD (

) outscores the other compounds, including DeRoy (

).

The 2-D interaction diagram (Figure 5) shows a schematic representation of the fit and intermolecular protein–ligand interactions for ParvD (

) and PKC

.